[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Compass Pathways Plc ADR (CMPS)

Compass Pathways Plc ADR (CMPS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,277,627
  • Shares Outstanding, K 128,923
  • Annual Sales, $ 0 K
  • Annual Income, $ -287,860 K
  • EBIT $ -179 M
  • EBITDA $ -179 M
  • 60-Month Beta 2.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 85.58% (+4.48%)
  • Historical Volatility 119.37%
  • IV Percentile 12%
  • IV Rank 5.67%
  • IV High 287.30% on 06/20/25
  • IV Low 73.46% on 03/19/26
  • Expected Move (DTE 5) 0.94 (9.52%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 2,341
  • Volume Avg (30-Day) 7,162
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 127,596
  • Open Int (30-Day) 102,555
  • Expected Range 8.97 to 10.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.45
  • Number of Estimates 6
  • High Estimate $-0.30
  • Low Estimate $-0.65
  • Prior Year $-0.44
  • Growth Rate Est. (year over year) -2.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.52 +79.53%
on 04/10/26
10.21 -2.94%
on 04/20/26
+4.19 (+73.25%)
since 04/08/26
3-Month
4.88 +103.07%
on 03/24/26
10.21 -2.94%
on 04/20/26
+3.72 (+60.10%)
since 02/06/26
52-Week
2.25 +340.44%
on 06/23/25
10.21 -2.94%
on 04/20/26
+6.15 (+163.56%)
since 05/08/25

Most Recent Stories

More News
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026

Compass management will host a conference call at 8:00 am ET (1:00 pm UK) 

CMPS : 9.91 (+5.54%)
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under...

CMPS : 9.91 (+5.54%)
Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

Trump signed an order to accelerate the regulatory progression of psychedelic therapies. Can Compass Pathways make use of it?

CMPS : 9.91 (+5.54%)
These 3 Psychedelic Stocks Activated After Trump's Executive Order

Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.

CMPS : 9.91 (+5.54%)
PSIL : 20.18 (-0.64%)
ATAI : 4.03 (+0.50%)
DFTX : 22.05 (-4.96%)
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standards...

CMPS : 9.91 (+5.54%)
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform...

CMPS : 9.91 (+5.54%)
Save This Psychedelic Stock Watchlist After Trump’s Latest Executive Order

From manufacturers to high volatility biotechs, these are the mind-bending med stocks our Senior Market Strategist is watching now.

CMPS : 9.91 (+5.54%)
PSIL : 20.18 (-0.64%)
ATAI : 4.03 (+0.50%)
JAZZ : 225.79 (-0.52%)
PBM : 5.59 (-7.14%)
This 4/20, Wall Street Is Betting on More Than Marijuana

Wall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative medicine.

IIPR : 57.29 (+1.24%)
CMPS : 9.91 (+5.54%)
CURLF : 3.8900 (-1.07%)
ATAI : 4.03 (+0.50%)
MSOS : 5.05 (-3.63%)
Trump Sends Compass Pathways Stock Soaring as He Backs Psychedelics. Should You Buy CMPS Here?

Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic medicines. But is it too late to invest in CMPS shares already?

CMPS : 9.91 (+5.54%)
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate...

CMPS : 9.91 (+5.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

COMPASS Pathways plc is a mental health care company. It operates principally in New York, USA. COMPASS Pathways plc is headquartered in London, UK.

See More

Key Turning Points

3rd Resistance Point 10.76
2nd Resistance Point 10.37
1st Resistance Point 10.14
Last Price 9.91
1st Support Level 9.51
2nd Support Level 9.12
3rd Support Level 8.89

See More

52-Week High 10.21
Last Price 9.91
Fibonacci 61.8% 7.17
Fibonacci 50% 6.23
Fibonacci 38.2% 5.29
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.